Skull base metastasis from papillary thyroid carcinoma: a report of three cases

Mutahir A Tunio¹

Mushabbab Al Asiri²

Khalid Hussain Al-Qahtani³

Sadiq Aldandan⁴

Khalid Riaz⁵

Yasser Bayoumi⁶

¹Radiation Oncology, King Fahad Medical City, Riyadh, Saudi Arabia;

²Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia;

³Department of Otolaryngology - Head and Neck Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia; ⁴Department of Histopathology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia; ⁵Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia; ⁶Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt

Abstract: Skull base metastasis from differentiated thyroid carcinoma, including papillary and follicular thyroid carcinoma, is a rare manifestation. Herein, we present three cases of skull base metastasis of papillary thyroid carcinoma. The mean age of the patients was 68.6 (65–74) years, and the mean interval between initial diagnosis and skull base metastasis was 56.3 (28–89) months. Cranial nerve palsies were seen in all patients. Intensity modulated radiation therapy to deliver 6,000–6,600 cGy to the skull base metastasis was given to all patients, in addition to partial resection in one patient. At the time of last follow-up, all skull base metastases were well controlled.

Keywords: papillary thyroid carcinoma, skull base metastasis, treatment

Introduction

Differentiated thyroid carcinoma, especially papillary thyroid carcinoma (PTC), commonly metastasizes to the regional lymph nodes, lungs, and bone. However, the brain is an uncommon site of metastasis, being found only in 0.15%–1.3% of cases.¹ Moreover; cerebellar metastases from PTC are exceptionally rare, with only 13 reported cases of cerebellar metastasis from PTC having been published so far.² Herein, we describe and discuss the signs and symptoms, diagnostic work-up, differential diagnosis, and management in three cases of cerebellar metastasis from PTC.

Case I

A 74-year-old female with a diagnosis of PTC, tall cell variant (pT3N1aM0), underwent total thyroidectomy, followed by radioactive iodine ablation (150 mCi) in February 2009. The patient was taking L-thyroxine 125 µg as thyroid replacement therapy, and remained in complete remission until June 2013, when she presented with a 3-month history of left upper neck pain. A pertinent neurological finding was ipsilateral cranial nerve XII palsy. Serum thyroglobulin levels were elevated (245.6 µg/L). No focus of abnormal tracer uptake was seen on I-131 whole body scintigraphy. Magnetic resonance imaging of the brain revealed an enhancing mass involving the left side of the clivus and the left occipital condyle (Figure 1). 18-Fluorodeoxyglucose positron emission tomography-computed tomography (CT) showed intense hypermetabolic activity (standardized uptake volume 138), corresponding to the destructive mass involving the clivus and left occipital condyle (Figure 2). A punch biopsy was taken from the clivus via the transnasal-transsphenoidal approach. Histopathology of the biopsy revealed tall papillary cells (height at least two or three times their width) mixed with small

Correspondence: Mutahir A Tunio
Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 59046, Saudi Arabia
Tel +966 11 288 9999
Fax +966 11 288 9999
Email drmutahirtunio@hotmail.com

Figure 1 Case 1: Axial view magnetic resonance imaging brain showing mass involving the left side of the clivus and left occipital condyle. The yellow arrow shows the mass involving the left side of the clivus and occipital condyle.

fragments of bone, and immunopositivity for thyroid transcription factor-1 and cytokeratin 19 confirmed the diagnosis of metastatic tall cell variant PTC (Figure 3). The patient was treated with external beam irradiation via intensity modulated radiotherapy (IMRT). A total dose of 6,600 cGy was delivered to the tumor in 33 fractions over 6.5 weeks. The treatment course was completed without any significant acute toxicity. Follow-up has been undertaken for 18 months, and the patient has remained clinically asymptomatic without any evidence of recurrence or distant metastases.

Figure 2 Case 1: PET/CT showing intense hypermetabolic activity (standardized uptake volume 138), corresponding to the destructive mass involving the left clivus and left occipital condyle.

Abbreviations: CT, computed tomography; PET, positron emission tomography.

Figure 3 Case 1: Hematoxylin–eosin staining showing tall papillary cells (height at least two to three times their width) thyroid carcinoma.

Case 2

A 67-year-old female with a diagnosis of PTC insular variant (pT4N1bM0) underwent total thyroidectomy and neck dissection in April 2011. After surgery, she was treated with radioactive iodine (150 mCi) and thyroid bed irradiation via IMRT with a dose of 66 Gy in 33 fractions. In September 2011, she developed lung metastasis, and was treated with a second radioactive iodine ablation dose (200 mCi). In August 2013, she started to complain of headache, diplopia, and facial weakness. Neurological findings were cranial nerve II, III, and V palsies on the left side. Serum thyroglobulin levels were found to be raised (3,200 µg/L). Whole body scintigraphy showed intense foci of uptake in the skull base and in both lungs. CT brain revealed an infiltrative enhancing mass occupying the right cavernous sinus and extending to the pituitary fossa and clivus (Figure 4A and B). Histopathological examination of a transnasal-transsphenoidal biopsied lesion revealed islands of small uniform cells, areas of tumor necrosis, and microfollicles with thyroglobulin, which confirmed the diagnosis of metastatic PTC, insular variant (Figure 5). The lesion was treated with IMRT, and a total dose of 6,000 cGy in 30 fractions was delivered to the tumor over 6 weeks without any significant acute toxicity. After completion of IMRT, the patient was given a third radioactive iodine ablation dose (150 mCi). At 14 months of follow-up, the patient was alive with progressive disease in the lungs, an elevated thyroglobulin level (5,000 µg/L), and a stable skull base lesion.

Case 3

A 65-year-old male underwent total thyroidectomy for multifocal PTC, follicular variant (pT3N1M0), followed

Figure 4 Case 2: (A) Axial and (B) sagittal views on computed tomography brain showing an infiltrative enhancing mass occupying the right cavernous sinus extending to the pituitary fossa and clivus.

by radioactive iodine ablation (150 mCi) in July 2006. The patient was on thyroid replacement therapy with L-thyroxine 150 µg, and was in complete remission until December 2013, when he presented with a 2-month history of headache, dysphagia, hoarseness, dysarthria, and hearing impairment. Pertinent neurological findings were cranial nerve IX, X, XI, and XII palsies on the left side (Collet-Sicard syndrome)

Figure 5 Case 2: Hematoxylin-eosin staining showing islands of small uniform cells, areas of tumor necrosis, and microfollicles.

with moderate sensorineural hearing loss and 100% word recognition on the affected side. Serum thyroglobulin levels were found to be elevated (46 µg/L). CT/magnetic resonance imaging brain revealed a large infiltrative mass involving the petrous, tympanic, and mastoid parts of the left temporal bone with intracranial extension. There was also evidence of invasion of the left sigmoid sinus, left internal jugular vein, and left internal auditory canal (Figure 6). The patient

Figure 6 Case 3: Computed tomography brain showing a large infiltrative mass involving the petrous, tympanic, and mastoid parts of the left temporal bone with intracranial extension.

Figure 7 Case 3: Follicular pattern of papillary thyroid carcinoma.

underwent left retromastoidal suboccipital craniotomy, with partial resection of the lesion. Histopathological examination confirmed the diagnosis of metastatic PTC, follicular variant (Figure 7). Following surgery, the residual tumor was treated with IMRT, using a total dose of 6,000 cGy in 30 fractions. After 12 months of follow-up, the patient remained well without any signs of progression or treatment-related complications.

Discussion

Skull base metastasis (SBM) of differentiated thyroid carcinoma shows a predominance of follicular thyroid carcinoma

(FTC), because FTC is more prone to spread via the hematogenous route to the lungs and bone.² However, SBM from PTC is rare. To date, only ten cases of SBM from PTC have been reported (Table 1).^{3–11} In agreement with the reported cases, SBM in our series were seen in the sixth and seventh decades of life, at a mean age of 68.6 (range 65–74) years, and the mean interval between initial diagnosis and SBM was 56.3 (range 28–89) years.^{3,8} In our series, two patients with aggressive variants of PTC (tall cell and insular) were recognized. According to the recent literature, these aggressive variants have a worse prognosis than classic PTC, and patients with these variants should be treated aggressively with thyroidectomy, neck dissection, and radioactive iodine, regardless of tumor size.¹²

The most common symptoms of SBM from PTC in our series were headache and cranial nerve palsies, which is in agreement with reports in the literature.^{11,12} However, a rare presentation of Collet-Sicard syndrome (cranial nerve IX, X, XI, and XII palsies) was also described, which is the first reported case in SBM from PTC.¹³ Diagnosis of SBM is challenging, because these lesions are often mistaken for chordoma, chondrosarcoma, meningioma, or schwannoma on CT and magnetic resonance imaging.¹⁴ Biopsies should be performed in such cases for definitive diagnosis. In our series, a biopsy was taken via the transnasal-transsphenoidal approach in two patients.

Treatment of SBM is challenging. Complete surgical resection is often difficult because of the presence of

Table 1 Previously published cases with skull base metastasis from papillary thyroid carcinoma

Reference	Age (years)/sex	Symptoms	Site	Histopathology	Treatment
Matsuno et al ³	56/F	Blurred vision, III, VI CN palsy	Sella turcica, sphenoid sinus	PTC, classic	TSH suppression, RAI
Bell et al ⁴	35/F	Hemianopsia, DI, amenorrhea	Sella turcica, pituitary gland	PTC, classic	Transsphenoidal surgery
Sziklas et al ⁵	44/M	Panhypopituitarism, hypogonadism	Sella turcica, pituitary gland	PTC, classic	Transsphenoidal surgery, RAI
Takami et al ⁶	41/M	Diplopia, subarachnoid hemorrhage	Cavernous sinus, cerebellopontine angle	PTC, classic	Surgery and gamma knife radiosurgery
Freeman et al ⁷	50/M	Horner's syndrome	Sphenoid sinus	PTC, classic	Surgery, RAI, RT
Masiukiewicz et al ⁸	1. 56/M 2. 55/F	1. Panhypopituitarism 2. Panhypopituitarism, blindness	1. Sella turcica, pituitary gland 2. Sella turcica, cavernous sinus	PTC, classic	RAI
Yan et al ⁹	73/M	Visual impairment, diplopia, epistaxis	Petrous bone, sella turcica, clivus, pterygoid plate, ethmoid sinus, infratemporal fossa, cavernous sinus	PTC, classic	Surgery, RAI
Hugh et al ¹⁰	64/F	Incidental finding	Petrous bone	PTC, classic	Surgery, RT
Kutluhan et al ¹¹	61/M	VI, VII, IX, X CN palsy	Temporooccipital bone	PTC, classic	Surgery, RT
Our series	1. 74/F 2. 67/F 3. 65/M	1. XII CN palsy 2. II, III, and V CN palsy 3. Collet-Sicard syndrome	1. Clivus, occipital condyle 2. Sella turcica, pituitary, cavernous sinus 3. Petrous, tympanic, mastoid, temporal bone with intracranial extension	1. PTC, tall cell 2. PTC, insular 3. PTC, follicular	1. IMRT 2. IMRT 3. Surgery, IMRT

Abbreviations: F, female; M, male; CN, cranial nerve; PTC, papillary carcinoma thyroid; TSH, thyroid stimulating hormone; RAI, radioactive iodine; DI, diabetes insipidus; RT, radiation therapy; IMRT, intensity modulated radiation therapy.

adjacent vital structures (brainstem, cochlea, and cranial nerves), cerebrospinal fluid leak, and bleeding. In our series, one patient had safe partial resection via a transcranial “far lateral” approach, which was found in agreement with the literature.¹⁵ For unresectable and residual tumors, radiation therapy is feasible option. With the advent of novel techniques in radiation therapy (IMRT, protons, carbon ions, and stereotactic radiosurgery), it is now possible to deliver a high dose to the tumor to achieve better local control without any serious acute toxicity, as seen in our series.¹⁶

In conclusion, SBM from PTC is a rare clinical entity, and is often associated with cranial nerve dysfunction. Histopathological tissue diagnosis should always be attempted to initiate effective treatment, which relies on a multidisciplinary approach to prolong disease-free and overall survival rates.

Acknowledgment

Written consent was taken from all patients for publication of this paper.

Disclosure

No grants or funding was received for this study. The authors have no conflicts of interest in this work.

References

1. Nigam A, Singh AK, Singh SK, Singh N. Skull metastasis in papillary carcinoma of thyroid: a case report. *World J Radiol.* 2012;4:286–290.
2. Mydlarz WK, Wu J, Aygun N, et al. Management considerations for differentiated thyroid carcinoma presenting as a metastasis to the skull base. *Laryngoscope.* 2007;117:1146–1152.
3. Matsuno A, Murakami M, Hoya K, et al. Clinicopathological and molecular histochemical review of skull base metastasis from differentiated thyroid carcinoma. *Acta Histochem Cytochem.* 2013;46:129–136.
4. Bell CD, Kovacs K, Horvath E, Smythe H, Asa S. Papillary carcinoma of thyroid metastatic to the pituitary gland. *Arch Pathol Lab Med.* 2001;125:935–938.
5. Sziklas JJ, Mathews J, Spencer RP, Rosenberg RJ, Ergin MT, Bower BF. Thyroid carcinoma metastatic to pituitary. *J Nucl Med.* 1985;26:1097.
6. Takami T, Ohata K, Tsuyuguchi N, et al. Cavernous sinus metastasis from thyroid papillary adenocarcinoma. *J Clin Neurosci.* 2002;9: 598–600.
7. Freeman JL, Gershon A, Liavaag PG, Walfish PG. Papillary thyroid carcinoma metastasizing to the sphenoid-ethmoid sinuses and skull base. *Thyroid.* 1996;6:59–61.
8. Masiukiewicz US, Nakchbandi IA, Stewart AF, Inzucchi SE. Papillary thyroid carcinoma metastatic to the pituitary gland. *Thyroid.* 1999;9: 1023–1027.
9. Yan B, Liu DG, Lu HL, Zhang QH. Images for diagnosis. Papillary thyroid microcarcinoma presenting as skull base metastasis. *Chin Med J (Engl).* 2010;123:2750–2752.
10. Hugh SC, Enepekides D, Wong J, Yeung R, Lin VY. Metastasis of follicular variant of papillary thyroid carcinoma masquerading as primary temporal bone tumour. *J Laryngol Otol.* 2011;125:528–532.
11. Kutluhan A, Yalçın G, Bozdemir K, Ozdemir E, Tarlak B, Bilgen AS. Papillary thyroid carcinoma with metastasis to the temporooccipital skull: a case report. *Kulak Burun Bogaz Ihtis Derg.* 2012;22: 160–163.
12. Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. *Ann Surg Oncol.* 2012;19:1874–1880.
13. Opie NJ, Ur-Rehman K, James GJ. A case of Collet-Sicard syndrome presenting to the Oral and Maxillofacial Surgery Department and a review of the literature. *Br J Oral Maxillofac Surg.* 2010;48:9–11.
14. Neelakantan A, Rana AK. Benign and malignant diseases of the clivus. *Clin Radiol.* 2014;69:1295–1303.
15. Benet A, Prevedello DM, Carrau RL, et al. Comparative analysis of the transcranial “far lateral” and endoscopic endonasal “far medial” approaches: surgical anatomy and clinical illustration. *World Neurosurg.* 2014;81:385–396.
16. Ohta N, Suzuki Y, Hasegawa A, Aoyagi M, Kakehata S. Carbon ion beam radiotherapy for sinonasal malignant tumors invading skull base. *Case Rep Otolaryngol.* 2014;2014:241856.

International Medical Case Reports Journal

Publish your work in this journal

The International Medical Case Reports Journal is an international, peer-reviewed open-access journal publishing original case reports from all medical specialties. Previously unpublished medical posters are also accepted relating to any area of clinical or preclinical science. Submissions should not normally exceed 2,000 words or

Submit your manuscript here: <http://www.dovepress.com/international-medical-case-reports-journal-journal>

4 published pages including figures, diagrams and references. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress